Clinical trial NCT06215716: A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: NASH With Fibrosis
MASH With Fibrosis
Lead sponsor: Akero Therapeutics, Inc
Sponsor class: INDUSTRY
First posted: 2024-01-22
Enrollment: 1650
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).

The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.


Eligibility criteria: Inclusion Criteria:

* Males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive, based on the date of the screening visit.
* Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes.
* Cohort 1: Biopsy-proven NASH/MASH. Must have had a liver biopsy obtained ≤ 180 days prior to screening with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:

  * Steatosis (scored 0 to 3),
  * Ballooning degeneration (scored 0 to 2), and
  * Lobular inflammation (scored 0 to 3).

Exclusion Criteria:

* Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.
* Presence of cirrhosis on liver biopsy (fibrosis stage 4).
* Type 1 or uncontrolled Type 2 diabetes.

Other inclusion and exclusion criteria may apply.

Primary outcomes:
measure: Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis
timeFrame: 52 Weeks
measure: Event-free survival
timeFrame: 240 Weeks
Secondary outcomes:
measure: Cohort 1 Only: Resolution of NASH/MASH and no worsening of fibrosis
timeFrame: 52 Weeks
measure: Cohort 1 Only: ≥ 1 stage improvement in fibrosis and no worsening of steatohepatitis
timeFrame: 52 Weeks
measure: Change from baseline of non-invasive markers of liver fibrosis
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of non-invasive markers of liver fibrosis
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of non-invasive markers of liver fibrosis
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of markers of liver injury
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of markers of liver injury
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of lipoproteins
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of markers of insulin sensitivity and glycemic control
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of markers of insulin sensitivity and glycemic control
timeFrame: 52 Weeks, 240 Weeks
measure: Change from baseline of body weight (kg)
timeFrame: 52 Weeks, 240 Weeks
measure: To assess the safety and tolerability of EFX through the reporting of extent of exposure (weeks)
timeFrame: 52 Weeks, 240 Weeks
measure: To assess the safety and tolerability of EFX through the reporting of adverse events (severity of events)
timeFrame: 52 Weeks, 240 Weeks
measure: To assess the safety and tolerability of EFX through the reporting of adverse events (frequency of events)
timeFrame: 52 Weeks, 240 Weeks
measure: To assess the safety and tolerability of EFX through the reporting of abnormal clinical laboratory tests, ECGs, ultrasounds, vital sign assessments (number of patients)
timeFrame: 52 Weeks, 240 Weeks
measure: To assess the immunogenicity of EFX through the reporting of antidrug antibodies (number of patients)
timeFrame: 52 Weeks, 240 Weeks
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Akero Clinical Study Site
state: Alabama
city: Dothan
country: United States
facility: Akero Clinical Study Site
state: Alabama
city: Chandler
country: United States
facility: Akero Clinical Study Site
state: Arizona
city: Flagstaff
country: United States
facility: Akero Clinical Study Site
state: Arizona
city: Mesa
country: United States
facility: Akero Clinical Study Site
state: Arizona
city: Peoria
country: United States
facility: Akero Clinical Study Site
state: Arizona
city: Tucson
country: United States
facility: Akero Clinical Study Site
state: Arizona
city: Tucson
country: United States
facility: Akero Clinical Study Site
state: Arizona
city: Tucson
country: United States
facility: Akero Clinical Study Site
state: Arizona
city: Conway
country: United States
facility: Akero Clinical Study Site
state: Arkansas
city: Jonesboro
country: United States
facility: Akero Clinical Study Site
state: Arkansas
city: Little Rock
country: United States
facility: Akero Clinical Study Site
state: Arkansas
city: North Little Rock
country: United States
facility: Akero Clinical Study Site
state: Arkansas
city: Chula Vista
country: United States
facility: Akero Clinical Study Site
state: California
city: Coronado
country: United States
facility: Akero Clinical Study Site
state: California
city: Escondido
country: United States
facility: Akero Clinical Study Site
state: California
city: Folsom
country: United States
facility: Akero Clinical Study Site
state: California
city: Inglewood
country: United States
facility: Akero Clinical Study Site
state: California
city: La Mesa
country: United States
facility: Akero Clinical Study Site
state: California
city: Lancaster
country: United States
facility: Akero Clinical Study Site
state: California
city: Long Beach
country: United States
facility: Akero Clinical Study Site
state: California
city: Los Angeles
country: United States
facility: Akero Clinical Study Site
state: California
city: Los Angeles
country: United States
facility: Akero Clinical Study Site
state: California
city: Newport Beach
country: United States
facility: Akero Clinical Study Site
state: California
city: Orange
country: United States
facility: Akero Clinical Study Site
state: California
city: Palm Springs
country: United States
facility: Akero Clinical Study Site
state: California
city: Pasadena
country: United States
facility: Akero Clinical Study Site
state: California
city: Redwood City
country: United States
facility: Akero Clinical Study Site
state: California
city: San Diego
country: United States
facility: Akero Clinical Study Site
state: California
city: San Diego
country: United States
facility: Akero Clinical Study Site
state: California
city: San Diego
country: United States
facility: Akero Clinical Study Site
state: California
city: San Francisco
country: United States
facility: Akero Clinical Study Site
state: California
city: Santa Maria
country: United States
facility: Akero Clinical Study Site
state: California
city: Aurora
country: United States
facility: Akero Clinical Study Site
state: Colorado
city: Colorado Springs
country: United States
facility: Akero Clinical Study Site
state: Colorado
city: Englewood
country: United States
facility: Akero Clinical Study Site
state: Colorado
city: New Haven
country: United States
facility: Akero Clinical Study Site
state: Connecticut
city: Bradenton
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Brandon
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Doral
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Fort Myers
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Gainesville
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Hialeah Gardens
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Inverness
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Jacksonville
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Lady Lake
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Lakewood Ranch
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Largo
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Maitland
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Margate
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Miami Gardens
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Miami Lakes
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Miami
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Miami
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Naples
country: United States
facility: Akero Clinical Study Site
state: Florida
city: New Port Richey
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Ocala
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Orlando
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Pembroke Pines
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Port Orange
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Sarasota
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Temple Terrace
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Venice
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Viera
country: United States
facility: Akero Clinical Study Site
state: Florida
city: West Palm Beach
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Winter Park
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Winter Park
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Zephyrhills
country: United States
facility: Akero Clinical Study Site
state: Florida
city: Columbus
country: United States
facility: Akero Clinical Study Site
state: Georgia
city: Gainesville
country: United States
facility: Akero Clinical Study Site
state: Georgia
city: Marietta
country: United States
facility: Akero Clinical Study Site
state: Georgia
city: Chicago
country: United States
facility: Akero Clinical Study Site
state: Illinois
city: Hammond
country: United States
facility: Akero Clinical Study Site
state: Indiana
city: South Bend
country: United States
facility: Akero Clinical Study Site
state: Indiana
city: West Des Moines
country: United States
facility: Akero Clinical Study Site
state: Iowa
city: Topeka
country: United States
facility: Akero Clinical Study Site
state: Kansas
city: Wichita
country: United States
facility: Akero Clinical Study Site
state: Kansas
city: Louisville
country: United States
facility: Akero Clinical Study Site
state: Kentucky
city: Bastrop
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: Covington
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: Houma
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: Marrero
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: Marrero
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: Metairie
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: New Orleans
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: New Orleans
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: Shreveport
country: United States
facility: Akero Clinical Study Site
state: Louisiana
city: Baltimore
country: United States
facility: Akero Clinical Study Site
state: Maryland
city: Glen Burnie
country: United States
facility: Akero Clinical Study Site
state: Maryland
city: Greenbelt
country: United States
facility: Akero Clinical Study Site
state: Maryland
city: South Dartmouth
country: United States
facility: Akero Clinical Study Site
state: Massachusetts
city: Novi
country: United States
facility: Akero Clinical Study Site
state: Michigan
city: Southfield
country: United States
facility: Akero Clinical Study Site
state: Michigan
city: Wyoming
country: United States
facility: Akero Clinical Study Site
state: Michigan
city: Ypsilanti
country: United States
facility: Akero Clinical Study Site
state: Michigan
city: Columbia
country: United States
facility: Akero Clinical Study Site
state: Missouri
city: Kansas City
country: United States
facility: Akero Clinical Study Site
state: Missouri
city: Las Vegas
country: United States
facility: Akero Clinical Study Site
state: Nevada
city: Las Vegas
country: United States
facility: Akero Clinical Study Site
state: Nevada
city: Reno
country: United States
facility: Akero Clinical Study Site
state: Nevada
city: Florham Park
country: United States
facility: Akero Clinical Study Site
state: New Jersey
city: Somers Point
country: United States
facility: Akero Clinical Study Site
state: New Jersey
city: Sparta
country: United States
facility: Akero Clinical Study Site
state: New Jersey
city: Santa Fe
country: United States
facility: Akero Clinical Study Site
state: New Mexico
city: Buffalo
country: United States
facility: Akero Clinical Study Site
state: New York
city: New York
country: United States
facility: Akero Clinical Study Site
state: New York
city: New York
country: United States
facility: Akero Clinical Study Site
state: New York
city: New York
country: United States
facility: Akero Clinical Study Site
state: New York
city: New York
country: United States
facility: Akero Clinical Study Site
state: New York
city: Chapel Hill
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: Charlotte
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: Durham
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: Fayetteville
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: Morehead City
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: New Bern
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: Raleigh
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: Statesville
country: United States
facility: Akero Clinical Study Site
state: North Carolina
city: Columbus
country: United States
facility: Akero Clinical Study Site
state: Ohio
city: Dayton
country: United States
facility: Akero Clinical Study Site
state: Ohio
city: Springboro
country: United States
facility: Akero Clinical Study Site
state: Ohio
city: Westlake
country: United States
facility: Akero Clinical Study Site
state: Ohio
city: Medford
country: United States
facility: Akero Clinical Study Site
state: Oregon
city: Philadelphia
country: United States
facility: Akero Clinical Study Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: Akero Clinical Study Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Akero Clinical Study Site
state: Pennsylvania
city: Columbia
country: United States
facility: Akero Clinical Study Site
state: South Carolina
city: Summerville
country: United States
facility: Akero Clinical Study Site
state: South Carolina
city: Chattanooga
country: United States
facility: Akero Clinical Study Site
state: Tennessee
city: Clarksville
country: United States
facility: Akero Clinical Study Site
state: Tennessee
city: Hermitage
country: United States
facility: Akero Clinical Study Site
state: Tennessee
city: Nashville
country: United States
facility: Akero Clinical Study Site
state: Tennessee
city: Amarillo
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Austin
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Austin
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Bellaire
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Brownsville
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Corpus Christi
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Dallas
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Dallas
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Dallas
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Dallas
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Dallas
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Denison
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Edinburg
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Edinburg
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Fort Worth
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Houston
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Houston
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Houston
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Lewisville
country: United States
facility: Akero Clinical Study Site
state: Texas
city: McAllen
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Antonio
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Antonio
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Antonio
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Antonio
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Antonio
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Antonio
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Antonio
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Marcos
country: United States
facility: Akero Clinical Study Site
state: Texas
city: San Marcos
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Waco
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Webster
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Wichita Falls
country: United States
facility: Akero Clinical Study Site
state: Texas
city: Ogden
country: United States
facility: Akero Clinical Study Site
state: Utah
city: Salt Lake City
country: United States
facility: Akero Clinical Study Site
state: Utah
city: Sandy
country: United States
facility: Akero Clinical Study Site
state: Utah
city: South Ogden
country: United States
facility: Akero Clinical Study Site
state: Utah
city: Falls Church
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Newport News
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Norfolk
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Richmond
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Richmond
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Richmond
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Richmond
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Roanoke
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Suffolk
country: United States
facility: Akero Clinical Study Site
state: Virginia
city: Seattle
country: United States
facility: Akero Clinical Study Site
state: Washington
city: Spokane
country: United States
facility: Akero Clinical Study Site
state: Washington
city: La Plata
country: Argentina
facility: Akero Clinical Study Site
state: Buenos Aires
city: Ramos Mejia
country: Argentina
facility: Akero Clinical Study Site
state: Buenos Aires
city: Buenos Aires
country: Argentina
facility: Akero Clinical Study Site
state: Distrito Federal
city: Buenos Aires
country: Argentina
facility: Akero Clinical Study Site
city: Buenos Aires
country: Argentina
facility: Akero Clinical Study Site
city: Buenos Aires
country: Argentina
facility: Akero Clinical Study Site
city: Broadmeadow
country: Australia
facility: Akero Clinical Study Site
state: New South Wales
city: Liverpool
country: Australia
facility: Akero Clinical Study Site
state: New South Wales
city: Westmead
country: Australia
facility: Akero Clinical Study Site
state: New South Wales
city: Adelaide
country: Australia
facility: Akero Clinical Study Site
state: South Australia
city: Caulfield South
country: Australia
facility: Akero Clinical Study Site
state: Victoria
city: Epping
country: Australia
facility: Akero Clinical Study Site
state: Victoria
city: Frankston
country: Australia
facility: Akero Clinical Study Site
state: Victoria
city: Heidelberg
country: Australia
facility: Akero Clinical Study Site
state: Victoria
city: Melbourne
country: Australia
facility: Akero Clinical Study Site
state: Victoria
city: Murdoch
country: Australia
facility: Akero Clinical Study Site
state: Western Australia
city: Nedlands
country: Australia
facility: Akero Clinical Study Site
state: Western Australia
city: Perth
country: Australia
facility: Akero Clinical Study Site
state: Western Australia
city: Edmonton
country: Canada
facility: Akero Clinical Study Site
state: Alberta
city: Hamilton
country: Canada
facility: Akero Clinical Study Site
state: Ontario
city: Toronto
country: Canada
facility: Akero Clinical Study Site
state: Ontario
city: Vaughan
country: Canada
facility: Akero Clinical Study Site
state: Ontario
city: Terrebonne
country: Canada
facility: Akero Clinical Study Site
state: Quebec
city: Nice Cedex 3
country: France
facility: Akero Clinical Study Site
state: Alpes-Maritimes
city: Strasbourg
country: France
facility: Akero Clinical Study Site
state: Bas-Rhin
city: Limoges Cedex
country: France
facility: Akero Clinical Study Site
state: Haute-Vienne
city: Clichy
country: France
facility: Akero Clinical Study Site
state: Hauts-de-Seine
city: Paris
country: France
facility: Akero Clinical Study Site
state: Ile-de-France
city: Vandœuvre-lès-Nancy
country: France
facility: Akero Clinical Study Site
state: Lorraine
city: Angers Cedex 9
country: France
facility: Akero Clinical Study Site
state: Maine-et-Loire
city: Toulouse
country: France
facility: Akero Clinical Study Site
state: Occitanie
city: Montpellier Cedex 5
country: France
facility: Akero Clinical Study Site
state: Provence Alpes Cote d'Azur
city: Marseille Cedex 08
country: France
facility: Akero Clinical Study Site
state: Provence-Alpes-Côte d'Azur
city: Lyon
country: France
facility: Akero Clinical Study Site
state: Rhone-Alpes
city: Versailles
country: France
facility: Akero Clinical Study Site
state: Yvelines, Île-de-France
city: Würzburg
country: Germany
facility: Akero Clinical Study Site
state: Bayern
city: Frankfurt am Main
country: Germany
facility: Akero Clinical Study Site
state: Hessen
city: Mainz
country: Germany
facility: Akero Clinical Study Site
state: Rheinland-Pfalz
city: Leipzig
country: Germany
facility: Akero Clinical Study Site
state: Sachsen
city: Leipzig
country: Germany
facility: Akero Clinical Study Site
state: Sachsen
city: Leipzig
country: Germany
facility: Akero Clinical Study Site
state: Saxony
city: Lübeck
country: Germany
facility: Akero Clinical Study Site
state: Schleswig-Holstein
city: Berlin
country: Germany
facility: Akero Clinical Study Site
city: Berlin
country: Germany
facility: Akero Clinical Study Site
city: New Delhi
country: India
facility: Akero Clinical Study Site
state: Delhi
city: New Delhi
country: India
facility: Akero Clinical Study Site
state: Delhi
city: Surat
country: India
facility: Akero Clinical Study Site
state: Gujarat
city: Vadodara
country: India
facility: Akero Clinical Study Site
state: Gujarat
city: Thiruvananthapuram
country: India
facility: Akero Clinical Study Site
state: Kerala
city: Dahegaon
country: India
facility: Akero Clinical Study Site
state: Maharashtra
city: Nagpur
country: India
facility: Akero Clinical Study Site
state: Maharashtra
city: Pune
country: India
facility: Akero Clinical Study Site
state: Maharashtra
city: Jaipur
country: India
facility: Akero Clinical Study Site
state: Rajasthan
city: Jaipur
country: India
facility: Akero Clinical Study Site
state: Rajasthan
city: Coimbatore
country: India
facility: Akero Clinical Study Site
state: Tamil Nadu
city: Hyderabad
country: India
facility: Akero Clinical Study Site
state: Telangana
city: Varanasi
country: India
facility: Akero Clinical Study Site
state: Uttar Pradesh
city: Kolkata
country: India
facility: Akero Clinical Study Site
state: West Bengal
city: Kolkata
country: India
facility: Akero Clinical Study Site
state: West Bengal
city: Kolkata
country: India
facility: Akero Clinical Study Site
state: West Bengal
city: Petah Tikva
country: Israel
facility: Akero Clinical Study Site
state: Central District
city: Ramat Gan
country: Israel
facility: Akero Clinical Study Site
state: Central District
city: Haifa
country: Israel
facility: Akero Clinical Study Site
state: Haifa District
city: Haifa
country: Israel
facility: Akero Clinical Study Site
state: Haifa District
city: Afula
country: Israel
facility: Akero Clinical Study Site
state: Northern District
city: Nahariya
country: Israel
facility: Akero Clinical Study Site
state: Northern District
city: Nazareth
country: Israel
facility: Akero Clinical Study Site
state: Northern District
city: Jerusalem
country: Israel
facility: Akero Clinical Study Site
city: Jerusalem
country: Israel
facility: Akero Clinical Study Site
city: Tel Aviv
country: Israel
facility: Akero Clinical Study Site
city: San Giovanni Rotondo
country: Italy
facility: Akero Clinical Study Site
state: Foggia
city: Rozzano
country: Italy
facility: Akero Clinical Study Site
state: Milan
city: Torino
country: Italy
facility: Akero Clinical Study Site
state: Turin
city: Bologna
country: Italy
facility: Akero Clinical Study Site
city: Foggia
country: Italy
facility: Akero Clinical Study Site
city: Messina
country: Italy
facility: Akero Clinical Study Site
city: Milan
country: Italy
facility: Akero Clinical Study Site
city: Milan
country: Italy
facility: Akero Clinical Study Site
city: Modena
country: Italy
facility: Akero Clinical Study Site
city: Napoli
country: Italy
facility: Akero Clinical Study Site
city: Novara
country: Italy
facility: Akero Clinical Study Site
city: Daegu
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Daegu Gwang'yeogsi [Taegu-Kwangyokshi]
city: Goyang-Si
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Gyeonggi-Do
city: Incheon
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Gyeonggi-do
city: Seongnam-si
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Gyeonggi-Do
city: Seongnam-si
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Gyeonggido [Kyonggi-do]
city: Daegu
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Gyeongsangbugdo [Kyongsangbuk-do]
city: Seoul
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
city: Seoul
country: Korea, Republic of
facility: Akero Clinical Study Site
state: Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
city: Wrocław
country: Poland
facility: Akero Clinical Study Site
state: Dolnoslaskie
city: Wrocław
country: Poland
facility: Akero Clinical Study Site
state: Dolnoslaskie
city: Krakow
country: Poland
facility: Akero Clinical Study Site
state: Malopolskie
city: Warsaw
country: Poland
facility: Akero Clinical Study Site
state: Mazowieckie
city: Warszawa
country: Poland
facility: Akero Clinical Study Site
state: Mazowieckie
city: Warszawa
country: Poland
facility: Akero Clinical Study Site
state: Mazowieckie
city: Gdańsk
country: Poland
facility: Akero Clinical Study Site
state: Pomorskie
city: Gdynia
country: Poland
facility: Akero Clinical Study Site
state: Pomorskie
city: Katowice
country: Poland
facility: Akero Clinical Study Site
state: Slaskie
city: Katowice
country: Poland
facility: Akero Clinical Study Site
state: Slaskie
city: Poznań
country: Poland
facility: Akero Clinical Study Site
state: Wielkopolskie
city: Łódź
country: Poland
facility: Akero Clinical Study Site
state: Łódzkie
city: Częstochowa
country: Poland
facility: Akero Clinical Study Site
state: Śląskie
city: Manati
country: Puerto Rico
facility: Akero Clinical Study Site
city: San Juan
country: Puerto Rico
facility: Akero Clinical Study Site
city: Sabadell
country: Spain
facility: Akero Clinical Study Site
state: Barcelona
city: Santander
country: Spain
facility: Akero Clinical Study Site
state: Cantabria
city: Majadahonda
country: Spain
facility: Akero Clinical Study Site
state: Madrid
city: Valencia
country: Spain
facility: Akero Clinical Study Site
state: València
city: Valencia
country: Spain
facility: Akero Clinical Study Site
state: València
city: Barcelona
country: Spain
facility: Akero Clinical Study Site
city: Madrid
country: Spain
facility: Akero Clinical Study Site
city: Madrid
country: Spain
facility: Akero Clinical Study Site
city: Sevilla
country: Spain
facility: Akero Clinical Study Site
city: Olten
country: Switzerland
facility: Akero Clinical Study Site
state: Solothurn
city: Bern
country: Switzerland
facility: Akero Clinical Study Site
city: Sankt Gallen
country: Switzerland
facility: Akero Clinical Study Site
city: Changhua City
country: Taiwan
facility: Akero Clinical Study Site
state: Changhua
city: Taichung City
country: Taiwan
facility: Akero Clinical Study Site
state: Taichung
city: Tainan City
country: Taiwan
facility: Akero Clinical Study Site
state: Tainan
city: Taipei City
country: Taiwan
facility: Akero Clinical Study Site
state: Taipei
city: Kaohsiung
country: Taiwan
facility: Akero Clinical Study Site
city: Tainan
country: Taiwan
facility: Akero Clinical Study Site
city: Taoyuan
country: Taiwan
facility: Akero Clinical Study Site
city: Yenimahalle
country: Turkey
facility: Akero Clinical Study Site
state: Ankara
city: Bornova
country: Turkey
facility: Akero Clinical Study Site
state: Izmir
city: Bursa
country: Turkey
facility: Akero Clinical Study Site
city: Rize
country: Turkey
facility: Akero Clinical Study Site
city: Birmingham
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: Cambridge
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: Liverpool
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: London
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: London
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: London
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: London
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: London
country: United Kingdom
facility: Akero Clinical Study Site
state: England
city: Newcastle-upon-Tyne
country: United Kingdom
facility: Akero Clinical Study Site
state: England
Study officials:
References: